Track the BridgeBio Oncology Therapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €736m. The latest transaction was disclosed on 6 July 2026 (Retenue fiscale). Among the most active insiders: Chen Bihua. The full history is free.
16
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate BridgeBio Oncology Therapeutics, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$24.90.
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
BridgeBio Oncology Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos innovadores para pacientes con cáncer. Se especializa en terapias dirigidas y enfoques basados en la genética.